Story perspectives

OKAVA Doses First Cat in Obesity Drug Trial

12/14/2025

50 4

Summary

Story summary

OKAVA Pharmaceuticals reports MEOW-1 trial of OKV-119, a glucagon-like peptide-1 (GLP-1) agonist for feline obesity, has dosed its first cat.
The trial targets weight loss and feline metabolic issues, including diabetes and kidney disease.
CEO Michael Klotsman says OKV-119 mimics fasting to improve insulin sensitivity without altering feeding routines.
If successful, a larger trial will follow and seek approval from the Food and Drug Administration (FDA) by 2028–2029.

1 of 1

Story summary

OKAVA Pharmaceuticals reports MEOW-1 trial of OKV-119, a glucagon-like peptide-1 (GLP-1) agonist for feline obesity, has dosed its first cat.
The trial targets weight loss and feline metabolic issues, including diabetes and kidney disease.
CEO Michael Klotsman says OKV-119 mimics fasting to improve insulin sensitivity without altering feeding routines.
If successful, a larger trial will follow and seek approval from the Food and Drug Administration (FDA) by 2028–2029.